The past decade has witnessed a surge in commercialized anti-VEGF agents for neovascular retinal diseases, including proliferative diabetic retinopathy, wet age-related macular degeneration (wet AMD), and choroidal neovascularization, with new formulations explored to meet the challenge of multiple ocular drug barriers and achieve sustained release [11, 12]. The gene discussed is VEGFA; the disease is wet macular degeneration.